GILD Earnings Date: Feb 9, 2027 (Estimated) — Gilead Sciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - General
Updated
When is GILD's next earnings date?
Gilead Sciences, Inc. (GILD) is expected to report Q4 2026 earnings on Tuesday, February 9, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.17 on revenue of $8.15B.
How did GILD do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Gilead Sciences, Inc. posted EPS of $2.55 versus the $2.19 estimate, a beat of 16.4%. Revenue was $8.30B against a $7.81B estimate.
How much does GILD stock move after earnings?
GILD beat EPS estimates in 8 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 3.8% (up or down) in the day after earnings.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
🤖 AI Earnings Analysis
Gilead delivered a strong Q3 beat, with $8.3B revenue topping $7.8B estimates and $2.55 EPS beating by $0.36; modest year-over-year gains suggest execution, not breakout growth.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 2.19 | 2.55 | +16.44% | $8.30B | ✅ Beat | — | — | — |
| 2026-08-04 | Q2 2026 | -7.14 | -6.75 | +5.46% | $7.80B | ✅ Beat | -2.58% | +0.39% | +10.62% |
| 2026-08-03 | -7.25 | -6.75 | +6.90% | $7.80B | ✅ Beat | +3.87% | +2.30% | +12.39% | |
| 2026-05-07 | Q1 2026 | 1.91 | 2.03 | +6.28% | $6.96B | ✅ Beat | -2.04% | -1.50% | -4.45% |
| 2026-02-10 | Q4 2025 | 1.83 | 1.86 | +1.64% | $7.92B | ✅ Beat | +5.82% | +3.74% | -1.38% |
| 2025-10-30 | Q3 2025 | 2.14 | 2.47 | +15.42% | $7.77B | ✅ Beat | +1.14% | +4.19% | +4.97% |
| 2025-08-07 | Q2 2025 | 1.95 | 2.01 | +3.08% | $7.08B | ✅ Beat | +8.28% | +7.92% | +5.08% |
| 2025-04-24 | Q1 2025 | 1.76 | 1.81 | +2.84% | $6.67B | ✅ Beat | -2.81% | -2.73% | +1.15% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $7.80B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Total HIV | 73.0% | $5.69B | — | — | — | — | — |
| Total Liver Disease | 11.2% | $877.0M | — | — | — | — | — |
| Total Oncology | 11.2% | $873.0M | — | — | — | — | — |
| Royalty, contract and other revenues | 2.3% | $176.0M | — | — | — | — | — |
| Total Other | 2.1% | $161.0M | — | — | — | — | — |
| Veklury | 0.3% | $23.0M | -81.0% | $552.0M | $302.0M | $121.0M | $277.0M |
By region
Q2 FY26 · $7.80B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 71.8% | $5.60B | +6.3% | $5.57B | $4.67B | $5.27B | $5.28B |
| Europe | 17.0% | $1.32B | +11.4% | $1.18B | $1.08B | $1.19B | $1.55B |
| Other International | 11.2% | $876.0M | +4.0% | $827.0M | $915.0M | $842.0M | $933.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.